tiprankstipranks
Advertisement
Advertisement

INCY Stock Latest News

Citizens biotech analysts hold an analyst/industry conference call
The FlyCitizens biotech analysts hold an analyst/industry conference call
2d ago
ALLO
CLLS
Buy Rating Reaffirmed as Opzelura’s Global Opportunity Expands and DCF-Supported $140 Price Target Is Maintained
PremiumRatings
Buy Rating Reaffirmed as Opzelura’s Global Opportunity Expands and DCF-Supported $140 Price Target Is Maintained
5d ago
INCY
Accenture, Estée Lauder, Luckin, Incyte, BILL Trending
PremiumWeekend Updates
Accenture, Estée Lauder, Luckin, Incyte, BILL Trending
7d ago
EL
ACN
Incyte Winds Down Itacitinib Rollover Study: What Investors Should Know
PremiumCompany Announcements
Incyte Winds Down Itacitinib Rollover Study: What Investors Should Know
8d ago
INCY
Incyte announces positive CHMP opinion of Opzelura Cream
PremiumThe Fly
Incyte announces positive CHMP opinion of Opzelura Cream
8d ago
INCY
Incyte price target raised to $113 from $103 at UBS
PremiumThe FlyIncyte price target raised to $113 from $103 at UBS
8d ago
INCY
Incyte price target raised to $105 from $103 at Truist
Premium
The Fly
Incyte price target raised to $105 from $103 at Truist
12d ago
INCY
Incyte Resolves Opzelura Medicaid Dispute, Gains One-Time Benefit
Premium
Company Announcements
Incyte Resolves Opzelura Medicaid Dispute, Gains One-Time Benefit
12d ago
8K
INCY
Incyte upgraded to Market Perform from Underperform at BMO Capital
PremiumThe Fly
Incyte upgraded to Market Perform from Underperform at BMO Capital
12d ago
INCY
Evan Seigerman Raises Incyte Price Target to $94 but Maintains Hold on Balanced View of Strategic Progress and Post-2029 LOE Risks
PremiumRatings
Evan Seigerman Raises Incyte Price Target to $94 but Maintains Hold on Balanced View of Strategic Progress and Post-2029 LOE Risks
12d ago
INCY
Incyte Japan announces approval of Minjuvi combination for DLBCL
PremiumThe Fly
Incyte Japan announces approval of Minjuvi combination for DLBCL
15d ago
INCY
Salveen Richter Reiterates Hold on Incyte as Mid‑Stage INCA033989 Data Align with Expectations Amid Rising Myelofibrosis Competition
PremiumRatings
Salveen Richter Reiterates Hold on Incyte as Mid‑Stage INCA033989 Data Align with Expectations Amid Rising Myelofibrosis Competition
19d ago
INCY
Seigerman Reiterates Sell on Incyte, Citing Weaker Pipeline Data and Jakafi Headwinds; Keeps $75 Price Target Unchanged
PremiumRatingsSeigerman Reiterates Sell on Incyte, Citing Weaker Pipeline Data and Jakafi Headwinds; Keeps $75 Price Target Unchanged
19d ago
INCY
Incyte Rated Hold as Mixed Myelofibrosis Data and Competitive Risks Keep Price Target Unchanged at $103
Premium
Ratings
Incyte Rated Hold as Mixed Myelofibrosis Data and Competitive Risks Keep Price Target Unchanged at $103
19d ago
INCY
Incyte: Buy Rating Reaffirmed on Promising INCA033989 Data and Risk-Reward, $124 Price Target Unchanged
Premium
Ratings
Incyte: Buy Rating Reaffirmed on Promising INCA033989 Data and Risk-Reward, $124 Price Target Unchanged
19d ago
INCY
Matt Phipps Reiterates Hold on Incyte as Encouraging INCA033989 Data Offset by Efficacy Moderation and Phase III Execution Risks
PremiumRatings
Matt Phipps Reiterates Hold on Incyte as Encouraging INCA033989 Data Offset by Efficacy Moderation and Phase III Execution Risks
19d ago
INCY
Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study
PremiumThe Fly
Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study
20d ago
INCY
MIRM
Incyte announces clinical data from two Phase 2 studies of INCA033989
PremiumThe Fly
Incyte announces clinical data from two Phase 2 studies of INCA033989
20d ago
INCY
Incyte announces results from Phase 3 frontMIND trial of tafasitamab
PremiumThe Fly
Incyte announces results from Phase 3 frontMIND trial of tafasitamab
20d ago
INCY
Incyte’s POD1UM-204 Endometrial Cancer Study Wraps Up, Setting the Stage for Key Retifanlimab Data
PremiumCompany AnnouncementsIncyte’s POD1UM-204 Endometrial Cancer Study Wraps Up, Setting the Stage for Key Retifanlimab Data
23d ago
INCY
Incyte Shareholders Back Board, Pay and Auditor Choices
Premium
Company Announcements
Incyte Shareholders Back Board, Pay and Auditor Choices
25d ago
8K
INCY
Incyte Upgraded on Vega Acquisition Synergies as Analyst Raises Price Target to $140 and Reiterates Buy
Premium
Ratings
Incyte Upgraded on Vega Acquisition Synergies as Analyst Raises Price Target to $140 and Reiterates Buy
25d ago
INCY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >